Get the Stockscreener App
8.41
11.19%
-1.06
After Hours:
8.25
-0.16
-1.90%
Contineum Therapeutics Inc stock is traded at $8.41, with a volume of 44,368.
It is down -11.19% in the last 24 hours and down -38.93% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$9.47
Open:
$9.38
24h Volume:
44,368
Relative Volume:
0.49
Market Cap:
$222.85M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-19.94
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
-14.10%
1M Performance:
-38.93%
6M Performance:
-50.12%
1Y Performance:
+0.00%
1-Day Range:
$8.31
$9.40
1-Week Range:
$8.31
$9.73
52-Week Range:
$8.31
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
8.41 | 222.85M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) 12% loss last week hit both individual investors who own 37% as well as institutions - Simply Wall St
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial - MSN
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS - Multiple Sclerosis News Today
Contineum Therapeutics (NASDAQ:CTNM) Earns “Outperform” Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics' (CTNM) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Contineum Therapeutics, Inc. Completes Enrollment in Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis - Marketscreener.com
Barclays PLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Geode Capital Management LLC Sells 27,745 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
State Street Corp Raises Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Update - MarketBeat
When the Price of (CTNM) Talks, People Listen - Stock Traders Daily
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Charles Schwab Investment Management Inc. Sells 8,477 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Franklin Resources Inc. Acquires 820,542 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
BNP Paribas Financial Markets Acquires 829 Shares of Farmers National Banc Corp. (NASDAQ:FMNB) - Defense World
BNP Paribas Financial Markets Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
BNP Paribas Financial Markets Has $129,000 Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
Contineum Therapeutics' SWOT analysis: biotech stock shows promise amid risks - Investing.com
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Fmr LLC Raises Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
(CTNM) On The My Stocks Page - Stock Traders Daily
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Shares Sold by Suvretta Capital Management LLC - MarketBeat
Contineum Therapeutics chief scientific officer sells stock worth $16,177 By Investing.com - Investing.com Nigeria
Contineum Therapeutics chief scientific officer sells stock worth $16,177 - Investing.com India
Avidity Biosciences to Participate in Upcoming Investor Conference - Quantisnow
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - BioSpace
Contineum Therapeutics chief scientific officer sells $101,420 in stock By Investing.com - Investing.com Australia
Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
(CTNM) Trading Signals - Stock Traders Daily
Sectoral Asset Management Inc's Strategic Acquisition in Contine - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Contineum Therapeutics Inc Stock (CTNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):